Group 1: Yingjie Electric - In 2024, Yingjie Electric's revenue is projected to be 1.78 billion yuan, a year-on-year increase of 0.59%, while net profit is expected to decline by 25.19% due to delays in revenue recognition in the photovoltaic industry, inventory write-downs, and increased expenses [1] - The company's cash flow from operating activities increased significantly to 601.77 million yuan, up by 46.20 million yuan year-on-year [1] - New orders decreased by approximately 40%, but the backlog remains over 2.7 billion yuan, with expectations for overseas photovoltaic orders to contribute to revenue recognition by 2025 [1] Group 2: Dingyang Technology - Dingyang Technology has established a comprehensive sales system in the global market, exporting to over 80 countries and regions [2] - The company has launched 10 new products in 2024 and 6 new products in 2025, focusing on high-end electronic testing and measurement instruments [2] - Dingyang aims to enhance its international brand influence and market share through a high-end development strategy and improved marketing channels [2] Group 3: Aibo Medical - Aibo Medical achieved total revenue of 1.41 billion yuan in 2024, a year-on-year increase of 48.24%, with net profit rising by 27.77% [3] - The company is experiencing significant growth in its Dragon Crystal® PR product line, although initial production quality and costs are challenges [3] - Aibo Medical's artificial lens business is expanding, with a notable increase in market share and a focus on high-end products to counteract price drops due to industry policies [3] Group 4: Libang Instruments - In Q1 2025, Libang Instruments reported revenue of 420 million yuan, a decline of 5%, with domestic sales down by 20% but international sales up by 7% [4] - The company is optimistic about domestic sales recovery due to improved market conditions and is leveraging AI technology in ultrasound imaging and smart healthcare [4] - Libang's gross margin is expected to rise to 57.92% in 2024, driven by increased sales of high-margin products [4]

1）爱博医疗 （易鑫安资管参与公司电话会议） 易鑫安成立于2011年4月，2014年4月获批了《私募投资基金管理人登记证书》。易鑫安拥有完整的投资研究团队，核心投资经理具有长期证券投 资经验，经历多轮牛熊市洗礼，对资本市场及上市公司有着长期、深刻的理解。核心投研成员均来自于国内外一流大学及行业资深人士，具有出 色的研究能力及敏锐的市场分析能力。成立十年来，易鑫安受到了主流金融机构及专业评级机构的认可，客户涵盖银行、保险、券商、信托、国 企、高净值客户等多种类型，囊括了英华奖、金阳光、金樟奖、金长江、百舸奖等多个行业重要奖项。易鑫安专注于二级市场投资，秉承日就月 将、行稳致远的投资理念，致力于打造不断迭代升级、勤勉尽责的学习型组织，以客户资产持续增值为目标，追求长期复合绝对收益，为客户创 造价值。 根据市场公开信息及4月28日披露的机构调研信息，知名私募易鑫安资管近期对1家上市公司进行了调研，相关名单如下： 调研纪要：2024年爱博医疗实现营业总收入14.10亿元，同比增长48.24%，净利润3.88亿元，同比增长27.77%。2025年Q1营收增长15.07%，但净利 润下滑。龙晶®PR产品推广顺利，医生反馈 ...